Integra LifeSciences (IART) to Release Quarterly Earnings on Monday

Integra LifeSciences (NASDAQ:IART) is scheduled to issue its quarterly earnings data before the market opens on Monday, November 4th. Analysts expect the company to announce earnings of $0.39 per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Monday, July 29th. The life sciences company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.01. The business had revenue of $418.20 million for the quarter, compared to analyst estimates of $413.07 million. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. Integra LifeSciences’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period last year, the firm earned $0.71 earnings per share. On average, analysts expect Integra LifeSciences to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Integra LifeSciences Stock Performance

NASDAQ IART opened at $18.95 on Monday. Integra LifeSciences has a 12-month low of $16.81 and a 12-month high of $45.42. The firm has a 50-day moving average price of $18.79 and a two-hundred day moving average price of $24.92. The company has a market capitalization of $1.49 billion, a P/E ratio of 37.90, a P/E/G ratio of 0.65 and a beta of 1.09. The company has a quick ratio of 2.10, a current ratio of 3.39 and a debt-to-equity ratio of 1.17.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on IART. Truist Financial reduced their price target on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research report on Monday, October 14th. Morgan Stanley increased their target price on Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a report on Monday, July 15th. Citigroup dropped their price target on Integra LifeSciences from $20.00 to $16.00 and set a “sell” rating for the company in a research note on Tuesday, October 1st. BTIG Research upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th. Finally, Bank of America dropped their target price on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research report on Monday, October 7th. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $26.50.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.